
Transire Bio: Innovating painless delivery of injectable drugs through inhaled medicine development.
Transpire Bio, founded with a mission to revolutionize drug delivery, focuses on developing inhaled medicines that provide painless alternatives to traditional injectable drugs. The company aims to enhance patient access to essential therapies and create innovative treatment options for serious diseases. Transpire Bio's core offerings include inhalation therapies for both lung and systemic diseases, positioning itself as a leader in the biotechnology sector with a strong emphasis on patient-centric solutions.
Notable figures associated with Transpire Bio include a leadership team of experienced professionals and subject matter technical experts dedicated to advancing inhalation therapy. The company has achieved significant milestones in its drug development pipeline, reflecting its commitment to cutting-edge science and patient care. Through strategic partnerships and a robust research agenda, Transpire Bio is making a substantial impact on the healthcare industry, offering promising alternatives to conventional drug delivery methods.

Respira Therapeutics

Qnovia
qnovia.com

Kinaset Therapeutics
kinasettx.com

Inhalon Biopharma
inhalon.com

Syntis Bio
syntis.bio

Portal Instruments

Surf Bio
surf.bio

Vitranu
vitranu.com

Spyryx Biosciences

i2o Therapeutics
i2obio.com

Pulmatrix
pulmatrix.com

BioQ Pharma
bioqpharma.com

Synspira

Aer Therapeutics

BioSuperior
bio-superior.com
Companies similar to Transpire Bio include Respira Therapeutics, Qnovia, Kinaset Therapeutics and Inhalon Biopharma.
Transpire Bio was founded in 2022.
Transpire Bio's headquarters is located in Weston, FL, US.
Transpire Bio's most recent funding round was for $10k (USD) in July 2023.
As of Jul 27, 2023, Transpire Bio has raised a total of $10k (USD).
Transpire Bio has 30 employees as of Feb 4, 2024.